Reply to: Comments on "Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting".

Authors

Federica Lo Prinzi, Margherita Rimini, Lorenzo Fornaro, Lorenza Rimassa, Andrea Casadei-Gardini

Published in

International journal of cancer. Oct 13, 2026. Epub Oct 13, 2026.

PMID:
42865151
Bibliographic data and abstract were imported from PubMed on 13 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.